Drugs / GS-100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06199531 | Feb 2024 → Mar 2027 expected | congenital disorder of deglycosylation 1 | Grace Science, LLC | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06199531 ↗ |